Login
Home / TXMD : NASDAQ
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

TherapeuticsMD, Inc.

$2.16 +$0.51 (+30.91%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$2.16
Day Range
$2.16$2.17
Year Range
$0.99$2.95
Market Cap
25M
AVG Volume
36.25K
Trailing/Forward PE
-114.89/11.37
PEG ratio
-9.77
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
NASDAQUS
Revenue (USD)
0250K500K750K1M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (USD)
-1.5M-1M-500K0500K1M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (USD)
-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (USD)
-4M-3M-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (USD)
-500K0500K1M1.5M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (USD)
-0.1-0.0500.0524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (USD)
01M2M3MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (USD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
-1-0.500.511.524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Return on Capital
-4%-2%0%2%4%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
05M10M15M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (USD)
012324 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (USD)
020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Employee Count
02004006002016201720182019202020212022202320242025
PE Ratio
050100150med 82.78Jun 23Jul 23Dec 25Jan 26Mar 26Jun 26Aug 26
Free Cash Flow Yield
-10%0%10%20%med 8.18%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
05101520med 7.4Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EV/EBITDA
00.10.20.30.40.5med 0.22May 23Jul 23Sep 23Nov 23Jan 24Mar 24Apr 24
Price/Operating Cashflow
0102030med 9.35Dec 23Apr 24Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
0.20.40.60.811.2med 0.63Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TherapeuticsMD, Inc.
TXMD
Stockpicker

Video analysis: TXMD

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: TXMD

TherapeuticsMD Announces Second Quarter 2026 Financial Results

gurufocus.com · 11 Aug 2026

TherapeuticsMD Announces Second Quarter 2026 Financial Results

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia
TherapeuticsMD Announces Second Quarter 2026 Financial Results

businesswire.com · 11 Aug 2026

TherapeuticsMD Announces Second Quarter 2026 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.